Anastrozole: one option of several
135 studies: a test or a strategy chooses among drugs. Page 1 of 2. Open to participants first (49), then studies with results posted, then the rest; newest registration first within each.
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingNCT07935317Phase 2How we knowReport a problem
- Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerRecruitingNCT07810088Phase 2How we knowReport a problem
- Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerRecruitingNCT07796880Phase 2How we knowReport a problem
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingNCT07782840Phase 2How we knowReport a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingNCT07729046Phase 2How we knowReport a problem
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingNCT07716046Phase 2How we knowReport a problem
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2How we knowReport a problem
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNCT07706933Not applicableHow we knowReport a problem
- Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingNCT07618923Phase 2How we knowReport a problem
- Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerRecruitingNCT07616453Phase 2How we knowReport a problem
- Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingNCT07616427Phase 2How we knowReport a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2How we knowReport a problem
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2How we knowReport a problem
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingNCT07527806Phase 2How we knowReport a problem
- Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3How we knowReport a problem
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingNCT07391774Phase 3How we knowReport a problem
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2How we knowReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3How we knowReport a problem
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingNCT07101159Phase 2How we knowReport a problem
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingNCT07061717Phase 3How we knowReport a problem
- CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)RecruitingNCT07019363Phase 3How we knowReport a problem
- Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyRecruitingNCT06953882Phase 2How we knowReport a problem
- The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicableHow we knowReport a problem
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2How we knowReport a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3How we knowReport a problem
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2How we knowReport a problem
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBCRecruitingNCT06235931Not applicableHow we knowReport a problem
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingNCT06218303Phase 1How we knowReport a problem
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingNCT06179303Phase 2How we knowReport a problem
- Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast CancerRecruitingNCT06149130Phase 2How we knowReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2How we knowReport a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingNCT06044623Phase 3How we knowReport a problem
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2How we knowReport a problem
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2How we knowReport a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingNCT05894239Phase 3How we knowReport a problem
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3How we knowReport a problem
- A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicableHow we knowReport a problem
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2How we knowReport a problem
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingNCT05792410Phase 1/2How we knowReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2How we knowReport a problem
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationNCT05645536Phase 3How we knowReport a problem
- Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)RecruitingNCT05640778Phase 2How we knowReport a problem
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2How we knowReport a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2How we knowReport a problem
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4How we knowReport a problem
- Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.RecruitingNCT05190094Phase 2How we knowReport a problem
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingNCT04886531Phase 2How we knowReport a problem
- De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)RecruitingNCT04852887Phase 3How we knowReport a problem
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingNCT04469764Phase 2How we knowReport a problem
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingNCT06001762Phase 2Results postedHow we knowReport a problem
- A Study of Abemaciclib in Indian Women With Advanced Breast CancerCompletedNCT04707196Phase 4Results postedHow we knowReport a problem
- Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTerminatedNCT03874325Phase 2Results postedHow we knowReport a problem
- Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerCompletedNCT03822468Phase 2Results postedHow we knowReport a problem
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedNCT03691493Phase 2Results postedHow we knowReport a problem
- Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.CompletedNCT03671330Phase 2Results postedHow we knowReport a problem
- MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results postedHow we knowReport a problem
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerCompletedNCT03179904Phase 2Results postedHow we knowReport a problem
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCompletedNCT03078751Phase 2Results postedHow we knowReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedHow we knowReport a problem
- A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results postedHow we knowReport a problem
- Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT02648477Phase 2Results postedHow we knowReport a problem
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results postedHow we knowReport a problem
- Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT02278120Phase 3Results postedHow we knowReport a problem
- Phase II Study of Everolimus Beyond ProgressionTerminatedNCT02269670Phase 2Results postedHow we knowReport a problem
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingNCT02246621Phase 3Results postedHow we knowReport a problem
- Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreTerminatedNCT02236572Phase 2Results postedHow we knowReport a problem
- Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results postedHow we knowReport a problem
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results postedHow we knowReport a problem
- Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast CancerTerminatedNCT01897441Not applicableResults postedHow we knowReport a problem
- AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)CompletedNCT01791985Phase 1/2Results postedHow we knowReport a problem
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyCompletedNCT01720602Not applicableResults postedHow we knowReport a problem
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3Results postedHow we knowReport a problem
- A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast CancerCompletedNCT01491737Phase 2Results postedHow we knowReport a problem
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerTerminatedNCT01484041Phase 1/2Results postedHow we knowReport a problem
- Reversing Hormone Resistance in Advanced Breast Cancer With PazopanibCompletedNCT01466972Phase 2Results postedHow we knowReport a problem
- Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCompletedNCT01446159Phase 2Results postedHow we knowReport a problem
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerActive, not recruitingNCT01272037Phase 3Results postedHow we knowReport a problem
- A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedNCT01160211Phase 3Results postedHow we knowReport a problem
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyCompletedNCT01153672Not applicableResults postedHow we knowReport a problem
- Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is ProgressingCompletedNCT00828854Phase 2Results postedHow we knowReport a problem
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCompletedNCT00728949Phase 2Results postedHow we knowReport a problem
- Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerTerminatedNCT00573755Phase 2Results postedHow we knowReport a problem
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Active, not recruitingNCT00310180Phase 3Results postedHow we knowReport a problem
- Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.CompletedNCT00240071Phase 2Results postedHow we knowReport a problem
- Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyActive, not recruitingNCT06957379Phase 2How we knowReport a problem
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerActive, not recruitingNCT06447623Phase 3How we knowReport a problem
- First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2How we knowReport a problem
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3How we knowReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2How we knowReport a problem
- Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerActive, not recruitingNCT05780567Phase 3How we knowReport a problem
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownNCT05439499Phase 3How we knowReport a problem
- Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.Status unknownNCT05411380Phase 2How we knowReport a problem
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1How we knowReport a problem
- H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyStatus unknownNCT05167643Not applicableHow we knowReport a problem
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4How we knowReport a problem
- Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast CancerActive, not recruitingNCT05041842Phase 2How we knowReport a problem
- Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerActive, not recruitingNCT04906395Phase 3How we knowReport a problem
- CB-103 Plus NSAI In Luminal Advanced Breast CancerTerminatedNCT04714619Phase 2How we knowReport a problem
- PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingNCT04584853Phase 3How we knowReport a problem
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast CancerWithdrawnNCT04316169Phase 1How we knowReport a problem